BLOG AND WHITEPAPERS
Recon takes an analytical look behind select developments in healthcare
Keep up with the Recon Strategy Insights
Get an email each time Recon takes an analytical look behind select developments in healthcare.
Search
- By Marc Herant
Incremental progress in the fight to treat heart failure
After a decade or more of relative quiescence in the 2000s, a volley of new therapies have come to the forefront in the pages of the NEJM: sacu…
- By Marc Herant
Cardiovascular health – go big or go narrow?
A follow up on the development of evinacumab (Regeneron), an inhibitor of ANGPLT3 (see this opinionated take from 2017), confirming the safety and LDL red…
- By Marc Herant
Small but real progress in ALS:
Despite enormous public attention and significant effort, ALS remains a disease for which the development of new therapies has been challenging. Animal models showed po…
- By Tess Niewood and Max Holle
OptumCare’s acquisitions usually make headlines. But what happens when the reporters leave? How is clinical capacity managed? What role do micro-acquisitions, recruiting and retirements play in advan…
- By Max Holle
Summary:
We conducted a comparative analysis of the referral networks of orthopedic surgeons in King County (the area around Seattle, WA) and Miami-Dade County.
Similarities
Bigger systems are better…
- By Marc Herant and Anja Schempf
PDF: An ADC renaissance: a resurgence of antibody drug conjugates for cancer
Summary:
Antibody-drug conjugates (ADCs) have seen a record number of approvals in 2020. This comes after a first era of i…